<DOC>
	<DOCNO>NCT01156077</DOCNO>
	<brief_summary>This open-label , multi-center , two-part , parallel-design study ass PK , safety , tolerability TR-701 FA active metabolite , TR-700 , follow single oral dose ( Part A ) IV dose ( Part B ) TR-701 FA 12 17 year old adolescent patient .</brief_summary>
	<brief_title>Pharmacokinetic ( PK ) Study Oral IV TR-701 FA Adolescent Patients</brief_title>
	<detailed_description />
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Torezolid phosphate</mesh_term>
	<criteria>male female , 12 17 year age , inclusive ; receive prophylaxis confirm suspected infection Gram positive bacteria receive concurrent antibiotic treatment Gram positive antibacterial activity stable condition female must premenarchal , surgically sterile , abstinent , practice effective method birth control males either surgically sterile , abstinent , practice effective method birth control relevant history seizure , clinically significant cardiac arrhythmia , cystic fibrosis , moderate severe renal impairment , physical condition could interfere interpretation study result acute chronic condition , opinion Investigator , would limit patient 's ability complete and/or participate clinical study physiciandiagnosed migraine headache history infection hepatitis significant hepatic disease female pregnant breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>antibiotic</keyword>
	<keyword>Adolescents receive antibiotic</keyword>
</DOC>